サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：がんワクチンの市場規模、シェア、動向分析レポート：適応症タイプ別、ワクチンタイプ別、技術タイプ別、地域別、およびセグメント予測：2023年～2030年
市場調査レポート
商品コード
1321366

がんワクチンの市場規模、シェア、動向分析レポート：適応症タイプ別、ワクチンタイプ別、技術タイプ別、地域別、およびセグメント予測：2023年～2030年

Cancer Vaccine Market Size, Share & Trends Analysis Report By Indication Type (Bladder, Cervical), By Vaccine Type (Preventive, Therapeutic), By Technology Type (Recombinant, Whole-cell), By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 130 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
がんワクチンの市場規模、シェア、動向分析レポート：適応症タイプ別、ワクチンタイプ別、技術タイプ別、地域別、およびセグメント予測：2023年～2030年
出版日: 2023年07月11日
発行: Grand View Research
ページ情報: 英文 130 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

がんワクチン市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界のがんワクチン市場規模は2023年から2030年にかけてCAGR 11.04%で拡大し、2030年には168億4,000万米ドルに達すると予測されています。

市場成長の背景には、人口の間でがんの有病率が増加していることがあります。WHOによると、がんは世界の主要死因であり、2020年には1,000万人が死亡し、前立腺がん、肺がん、乳がん、結腸がん、皮膚がん、胃がんなどが最も多く、世界では6人に1人が死亡しています。症例数の増加は、高齢者人口の増加や、経済・社会の発展に伴う特定のがん原因の有病率の変化など、さまざまな要因によるところが大きいです。これは特に新興経済諸国で見られ、貧困に関連するがんという点で、一般的な変化が観察されます。これは先進経済諸国とは対照的で、ライフスタイル障害に関連する症例が増えています。

WHOによると、肥満、ある種の感染症、放射線被曝は、患者数の増加に関連する主な要因です。さらに、予防分野における技術の進歩により、ワクチンの需要は世界的に大幅に増加しています。バイオマーカーおよびマスサイトメトリーの開発に対するFDAの支援、創薬および診断のためのさまざまなフローサイトメトリー試薬の発売、携帯性と精度を容易にする技術的に進歩した小型化装置、細胞およびビーズベースのフローサイトメトリー技術の開拓は、市場の成長を後押しする主な要因です。組織によるがんに対する認識を高めるための様々なプログラムが、世界の革新的ワクチンの需要増加の主な要因となっています。全米子宮頸がん連合、CDC、WHO、米国予防サービス作業部会などが子宮頸がん検診を増やすために行っている協力やパートナーシップは、予測期間中に市場成長を増大させると予想される主な要因です。

さらに、様々なワクチンの開発・製剤化に携わる主な企業は、新規ワクチンの開発や業界における競争力の維持のため、共同研究や提携に注力しています。さらに、この疾患の予防需要の高まりに対応するため、複数の企業が新規ワクチンの開発に取り組んでいます。例えば、2023年2月、BioNTech社は、2023年9月からワクチンの臨床試験を開始する計画を発表し、2030年までには市場に投入される見込みです。2023年3月、クリーブランド・クリニックの調査チームは、最も致死率の高いトリプルネガティブ乳がん予防ワクチンの上市に向けた次のステップを発表しました。

がんワクチン市場レポートハイライト

  • 2022年には、有病率の上昇に伴う疾患予防の必要性から、予防ワクチンタイプが最大の売上シェアを占めました。
  • 子宮頸がん適応症タイプは、有病率の上昇により、予測期間中に最も速い成長率を記録すると予想されます。
  • 技術タイプ別では、組換え技術から開発されたワクチンの入手可能性が高いことから、組換えワクチン分野が2022年の世界産業を支配しました。
  • 事業を展開する主要企業は、市場での地位とシェアを維持するため、常に製品の上市と地理的拡大に注力しています。
  • 北米は、ヘルスケアのインフラが整っていること、がんの有病率が高いこと、主要企業が存在すること、適切なワクチン接種サービスが受けられることなどから、2022年に最大の売上シェアを占めました。

目次

第1章 がんワクチン市場：調査手法と範囲

第2章 がんワクチン市場：エグゼクティブサマリー

  • 市場スナップショット
  • ワクチンタイプと適応症タイプのスナップショット
  • 技術タイプのスナップショット
  • 競合情勢のスナップショット

第3章 がんワクチン市場：業界の展望

  • 市場系統の見通し
    • 親市場の系統の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因
    • 市場抑制要因分析
  • SWOT分析、要因別（政治・法律、経済・技術）
  • 業界分析- ポーター
  • 償還と規制のシナリオ
  • 大規模な取引と戦略的提携
    • 新製品の発売
    • 取得
    • 拡張
    • パートナーシップ
    • マーケティングとプロモーション

第4章 がんワクチン市場：競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業の分類
  • ベンダー情勢
  • 公開会社
  • 非公開会社
  • 地域のネットワークマップ

第5章 がんワクチン市場：ワクチンタイプのビジネス分析

  • 定義と範囲
  • ワクチンタイプの市場シェア分析、2022年および2030年
  • 世界のがんワクチン市場、ワクチンタイプ別、2018年から2030年
  • がんワクチン市場：ワクチンタイプの変動分析
  • がん予防ワクチン
  • 治療用がんワクチン
  • その他

第6章 がんワクチン市場：適応症タイプのビジネス分析

  • 定義と範囲
  • 適応症タイプの市場シェア分析、2022年および2030年
  • 世界のがんワクチン市場、適応症タイプ、2018年から2030年
  • がんワクチン市場：適応症タイプの変動分析
  • 前立腺がん
  • 膀胱がん
  • メラノーマ
  • 子宮頸がん
  • その他

第7章 がんワクチン市場：技術タイプのビジネス分析

  • 定義と範囲
  • 技術タイプの市場シェア分析、2022年および2030年
  • 世界のがんワクチン市場、技術タイプ別、2018年から2030年
  • がんワクチン市場：技術タイプの変動分析
  • 組換えがんワクチン
  • 全細胞がんワクチン
  • ウイルスベクターおよびDNAがんワクチン
  • その他

第8章 がんワクチン市場：地域ビジネス分析

  • 定義と範囲
  • 地域市場シェア分析、2022年および2030年
  • 地域市場ダッシュボード
  • 地域市場のスナップショット
  • SWOT分析、要因別（政治・法律、経済・技術）
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場規模、予測、動向分析、2022年から2030年まで
  • 北米
    • 北米ワクチン市場推計・予測、2018年から2030年
    • 米国
    • カナダ
  • 欧州
    • 欧州がんワクチン市場、2018～2030年
    • 英国
    • ドイツ
    • スペイン
    • フランス
    • イタリア
    • ノルウェー
    • デンマーク
    • スウェーデン
  • アジア太平洋地域
    • アジア太平洋のがんワクチン市場、2018～2030年
    • 日本
    • 中国
    • インド
    • 韓国
    • タイ
    • オーストラリア
  • ラテンアメリカ
    • ラテンアメリカのがんワクチン市場、2018年から2030年
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • MEAがんワクチン市場、2018年～2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第9章 がんワクチン市場：企業概要

  • 企業の分類
  • 戦略マッピング
    • 新製品の発売
    • パートナーシップ
    • 取得
    • コラボレーション
    • 資金調達
  • 主要企業の市場シェア分析、2022年
  • 企業プロファイル
    • Merck & Co., Inc.
    • GSK plc
    • Dendreon Pharmaceuticals LLC.
    • Dynavax Technologies.
    • Ferring B.V.
    • Amgen, Inc.
    • Moderna, Inc.
    • Sanofi
    • AstraZeneca
    • Bristol-Myers Squibb Company
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 Global Cancer Vaccine Market, By Region, 2018 - 2030 (USD Million)
  • Table 4 Global Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 5 Global Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 6 Global Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 7 North America Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
  • Table 8 North America Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 9 North America Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 10 North America Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 11 U.S. Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 12 U.S. Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 13 U.S. Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 14 Canada Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 15 Canada Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 16 Canada Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 17 Europe Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
  • Table 18 Europe Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 19 Europe Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 20 Europe Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 21 UK Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 22 UK Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 23 UK Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 24 Germany Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 25 Germany Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 26 Germany Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 27 France Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 28 France Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 29 France Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 30 Italy Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 31 Italy Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 32 Italy Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 33 Spain Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 34 Spain Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 35 Spain Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 36 Denmark Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 37 Denmark Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 38 Denmark Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 39 Sweden Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 40 Sweden Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 41 Sweden Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 42 Norway Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 43 Norway Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 44 Norway Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 49 Japan Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 50 Japan Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 51 Japan Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 52 China Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 53 China Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 54 China Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 55 India Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 56 India Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 57 India Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 58 South Korea Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 59 South Korea Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 60 South Korea Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 61 Australia Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 62 Australia Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 63 Australia Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 64 Thailand Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 65 Thailand Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 66 Thailand Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 67 Latin America Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
  • Table 68 Latin America Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 69 Latin America Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 70 Latin America Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 71 Brazil Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 72 Brazil Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 73 Brazil Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 74 Mexico Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 75 Mexico Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 76 Mexico Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 77 Argentina Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 78 Argentina Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 79 Argentina Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 85 Saudi Arabia Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 87 South Africa Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 88 South Africa Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 89 South Africa Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 90 UAE Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 91 UAE Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 92 UAE Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Cancer Vaccine Market Segmentation
  • Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 11 Penetration & Growth Prospect Mapping
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Cancer vaccine market: Vaccine Type outlook and key takeaways
  • Fig. 15 Cancer vaccine market: Vaccine Type movement analysis & market share 2022 & 2030
  • Fig. 16 Preventive cancer vaccine market, 2018 - 2030 (USD Million)
  • Fig. 17 Therapeutic cancer vaccine market, 2018 - 2030 (USD Million)
  • Fig. 18 Others market, 2018 - 2030 (USD Million)
  • Fig. 19 Cancer vaccine market: Indication type outlook and key takeaways
  • Fig. 20 Cancer vaccine market: Indication type movement analysis & market share 2022 & 2030
  • Fig. 21 Prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 22 Bladder cancer market, 2018 - 2030 (USD Million)
  • Fig. 23 Melanoma market, 2018 - 2030 (USD Million)
  • Fig. 24 Cervical cancer market, 2018 - 2030 (USD Million)
  • Fig. 25 Others market, 2018 - 2030 (USD Million)
  • Fig. 26 Cancer vaccine market: Technology type outlook and key takeaways
  • Fig. 27 Cancer vaccine market: Technology type movement analysis & market share 2022 & 2030
  • Fig. 28 Recombinant cancer vaccine market, 2018 - 2030 (USD Million)
  • Fig. 29 Whole-cell cancer vaccine market, 2018 - 2030 (USD Million)
  • Fig. 30 Viral vector and DNA cancer vaccine market, 2018 - 2030 (USD Million)
  • Fig. 31 Other technologies market, 2018 - 2030 (USD Million)
  • Fig. 32 Regional Marketplace: Key Takeaways
  • Fig. 33 Regional Outlook, 2022 & 2030
  • Fig. 34 Regional Market Dashboard
  • Fig. 35 Regional Market Place: Key Takeaways
  • Fig. 36 North America, SWOT Analysis
  • Fig. 37 Europe, SWOT Analysis
  • Fig. 38 Asia Pacific, SWOT Analysis
  • Fig. 39 Latin America, SWOT Analysis
  • Fig. 40 MEA, SWOT Analysis
  • Fig. 41 North America
  • Fig. 42 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 43 U.S. Key Country Dynamics
  • Fig. 44 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 45 Canada Key Country Dynamics
  • Fig. 46 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Europe
  • Fig. 48 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 49 UK Key Country Dynamics
  • Fig. 50 UK Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Germany Key Country Dynamics
  • Fig. 52 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 53 France Key Country Dynamics
  • Fig. 54 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Italy Key Country Dynamics
  • Fig. 56 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 57 Spain Key Country Dynamics
  • Fig. 58 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 59 Denmark Key Country Dynamics
  • Fig. 60 Denmark Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 61 Sweden Key Country Dynamics
  • Fig. 62 Sweden Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 63 Norway Key Country Dynamics
  • Fig. 64 Norway Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 65 Asia Pacific
  • Fig. 66 Asia Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 67 Japan Key Country Dynamics
  • Fig. 68 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 69 China Key Country Dynamics
  • Fig. 70 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 71 India Key Country Dynamics
  • Fig. 72 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 73 Australia Key Country Dynamics
  • Fig. 74 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 75 Thailand Key Country Dynamics
  • Fig. 76 Thailand Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 77 South Korea Key Country Dynamics
  • Fig. 78 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 79 Latin America
  • Fig. 80 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 81 Brazil Key Country Dynamics
  • Fig. 82 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 83 Mexico Key Country Dynamics
  • Fig. 84 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 85 Argentina Key Country Dynamics
  • Fig. 86 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 87 MEA
  • Fig. 88 MEA Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 89 South Africa Key Country Dynamics
  • Fig. 90 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 91 Saudi Arabia Key Country Dynamics
  • Fig. 92 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 93 UAE Key Country Dynamics
  • Fig. 94 UAE Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 95 Kuwait Key Country Dynamics
  • Fig. 96 Kuwait Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 97 Strategy Mapping
目次
Product Code: GVR-4-68040-096-2

Cancer Vaccine Market Growth & Trends

The global cancer vaccine market size is expected to reach USD 16.84 billion by 2030, expanding at a CAGR of 11.04% from 2023 to 2030, according to a new report by Grand View Research, Inc. The market growth is attributed to the increasing prevalence of cancer among the population. According to the WHO, it is a leading cause of death globally, which accounted for 10 million deaths in 2020, with prostate, lung, breast, colon, skin, and stomach cancers being the most common types causing one in every six deaths worldwide. A rise in the number of cases can be majorly attributed to various factors, such as the rising geriatric population and changing prevalence of certain causes of cancer associated with economic & social development. This is particularly seen in emerging economies, wherein a general shift is observed in terms of cancers associated with poverty, which is a contrast to developed economies, wherein cases have increasingly been associated with lifestyle disorders.

According to the WHO, obesity, certain types of infections, and exposure to radiation are major factors associated with an increase in the number of cases. Moreover, the demand for vaccines is significantly increasing worldwide owing to technological advancements in the field of prevention. FDA support for developing biomarkers & mass cytometry; launch of various flow cytometry reagents for drug discovery & diagnosis; technologically advanced miniaturized devices, facilitating portability & precision; development of cell- & bead-based flow cytometry techniques are major factors boosting the market growth. Various programs to increase awareness about cancer by organizations are key factors responsible for the increased demand for innovative vaccines worldwide. Collaborations and partnerships undertaken by the National Cervical Cancer Coalition, CDC, WHO, the U.S. Preventive Services Task Force, and others for increasing screening of cervical cancer are major factors expected to augment the market growth during the forecast period.

Furthermore, key players involved in developing and formulating various vaccines are focusing on collaborations and partnerships to develop novel vaccines and to maintain their competitive position in the industry. Moreover, several players are involved in the development of novel vaccines to meet the rising demand for prevention of the condition. For instance, in February 2023, BioNTech announced plans to proceed with clinical trials for its vaccine from September 2023, which is expected to be launched in the market before 2030. In March 2023, Researchers at Cleveland Clinic announced the next step toward the launch of a vaccine for the prevention of triple-negative breast cancer, which is one of the most lethal forms of the condition.

Cancer Vaccine Market Report Highlights

  • The preventive vaccine type segment held the largest revenue share in 2022 owing to the need for preventing the condition due to the rising prevalence
  • The cervical cancer indication type segment is expected to register the fastest growth rate over the forecast period due to the rising disease prevalence
  • On the basis of technology type, the recombinant vaccine segment dominated the global industry in 2022 due to the high availability of vaccines developed from recombinant technology
  • Key players operating are constantly focusing on product launches and geographical expansions to maintain their market position and share
  • North America held the largest revenue share in 2022 on account of the better healthcare infrastructure, the high prevalence of cancer, the presence of key players, and the availability of proper vaccination service

Table of Contents

Chapter 1 Cancer Vaccine Market: Methodology And Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment Definitions
      • 1.1.1.1 Vaccine Type Segment
      • 1.1.1.2 Technology type segment
      • 1.1.1.3 Indication type segment
  • 1.2 Regional Scope
  • 1.3 Estimates and Forecast Timeline
  • 1.4 Objectives
    • 1.4.1 Objective - 1
    • 1.4.2 Objective - 2
    • 1.4.3 Objective - 3
  • 1.5 Research Methodology
  • 1.6 Information Procurement
    • 1.6.1 Purchased Database
    • 1.6.2 Gvr's Internal Database
    • 1.6.3 Secondary Sources
    • 1.6.4 Primary Research
  • 1.7 Information Or Data Analysis
    • 1.7.1 Data Analysis Models
  • 1.8 Market Formulation & Validation
  • 1.9 Model Details
    • 1.9.1 Commodity Flow Analysis
  • 1.10 List of Secondary Sources
  • 1.11 List of Abbreviations

Chapter 2 Cancer Vaccine Market: Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Vaccine Type and Indication Type Snapshot
  • 2.3 Technology Type Snapshot
  • 2.4 Competitive Landscape Snapshot

Chapter 3 Cancer Vaccine Market: Industry Outlook

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Lineage Outlook
    • 3.1.2 Related/Ancillary Market Outlook
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Market Dynamics
    • 3.3.1 Market Drivers
      • 3.3.1.1 Increasing Prevalence of cancer
      • 3.3.1.2 Growing investments and governmental funding in the development of cancer vaccines
      • 3.3.1.3 Increasing demand for cancer vaccines
      • 3.3.1.4 Launch of new cancer vaccines
    • 3.3.2 Market Restraint Analysis
      • 3.3.2.1 Complex And Time-Consuming Regulatory Approval Process
      • 3.3.2.2 High Price Associated With Vaccines
  • 3.4 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
  • 3.5 Industry Analysis - Porter's
  • 3.6 Reimbursement & Regulatory Scenario
  • 3.7 Major Deals & Strategic Alliances
    • 3.7.1 New Product Launch
    • 3.7.2 Acquisition
    • 3.7.3 Expansion
    • 3.7.4 Partnerships
    • 3.7.5 Marketing & Promotions

Chapter 4 Cancer Vaccine Market: Competitive Landscape

  • 4.1 Recent developments & impact analysis, by key market participants
    • 4.1.1 Ansoff Matrix
  • 4.2 Company Categorization
    • 4.2.1 Innovators
      • 4.2.1.1 Market Differentiators
  • 4.3 Vendor Landscape
    • 4.3.1 List Of Key Distributors And Channel Partners
    • 4.3.2 Key Customers
    • 4.3.3 Key Company Market Share Analysis, 2022
  • 4.4 Public Companies
    • 4.4.1 Competitive Dashboard Analysis
  • 4.5 Private Companies
    • 4.5.1 List Of Key Emerging Companies
  • 4.6 Regional Network Map

Chapter 5 Cancer Vaccine Market: Vaccine Type Business Analysis

  • 5.1 Definition And Scope
  • 5.2 Vaccine Type Market Share Analysis, 2022 & 2030
  • 5.3 Global Cancer Vaccine Market, By Vaccine Type, 2018 To 2030
  • 5.4 Cancer Vaccine Market: Vaccine Type Movement Analysis
  • 5.5 Preventive Cancer Vaccines
    • 5.5.1 Preventive Cancer Vaccines Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.6 Therapeutic Cancer Vaccines
    • 5.6.1 Therapeutic Cancer Vaccines Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.7 Others
    • 5.7.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6 Cancer Vaccine Market: Indication Type Business Analysis

  • 6.1 Definition And Scope
  • 6.2 Indication Type Market Share Analysis, 2022 & 2030
  • 6.3 Global Cancer Vaccine Market, By Indication Type, 2018 To 2030
  • 6.4 Cancer Vaccine Market: Indication Type Movement Analysis
  • 6.5 Prostate Cancer
    • 6.5.1 Prostate Cancer Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.6 Bladder Cancer
    • 6.6.1 Bladder Cancer Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.7 Melanoma
    • 6.7.1 Melanoma Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.8 Cervical Cancer
    • 6.8.1 Cervical Cancer Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.9 Others
    • 6.9.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 7 Cancer Vaccine Market: Technology Type Business Analysis

  • 7.1 Definition And Scope
  • 7.2 Technology Type Market Share Analysis, 2022 & 2030
  • 7.3 Global Cancer Vaccine Market, By Technology Type, 2018 To 2030
  • 7.4 Cancer Vaccine Market: Technology Type Movement Analysis
  • 7.5 Recombinant Cancer Vaccines
    • 7.5.1 Recombinant Cancer Vaccines Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.6 Whole-Cell Cancer Vaccines
    • 7.6.1 Whole-Cell Cancer Vaccines Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.7 Viral Vector And Dna Cancer Vaccines
    • 7.7.1 Viral Vector And Dna Cancer Vaccines Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.8 Others
    • 7.8.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 8 Cancer Vaccine Market: Regional Business Analysis

  • 8.1 Definition & Scope
  • 8.2 Regional Market Share Analysis, 2022 & 2030
  • 8.3 Regional Market Dashboard
  • 8.4 Regional Market Snapshot
  • 8.5 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
    • 8.5.1 North America
    • 8.5.2 Europe
    • 8.5.3 Asia Pacific
    • 8.5.4 Latin America
    • 8.5.5 Mea
  • 8.6 Market Size, & Forecasts, Trend Analysis, 2022 To 2030
  • 8.7 North America
    • 8.7.1 North America Cancer Vaccine Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 8.7.2 U.S.
      • 8.7.2.1 U.S. Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.7.2.2 Key Country Dynamics
      • 8.7.2.3 Regulatory Framework
      • 8.7.2.4 Competitive Scenario
    • 8.7.3 Canada
      • 8.7.3.1 Canada Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.7.3.2 Key Country Dynamics
      • 8.7.3.3 Regulatory Framework
      • 8.7.3.4 Competitive Scenario
  • 8.8 Europe
    • 8.8.1 Europe Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 8.8.2 UK
      • 8.8.2.1 UK Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.8.2.2 Key Country Dynamics
      • 8.8.2.3 Regulatory Framework
      • 8.8.2.4 Competitive Scenario
    • 8.8.3 Germany
      • 8.8.3.1 Germany Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.8.3.2 Key Country Dynamics
      • 8.8.3.3 Regulatory Framework
      • 8.8.3.4 Competitive Scenario
    • 8.8.4 Spain
      • 8.8.4.1 Spain Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.8.4.2 Key Country Dynamics
      • 8.8.4.3 Regulatory Framework
      • 8.8.4.4 Competitive Scenario
    • 8.8.5 France
      • 8.8.5.1 France Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.8.5.2 Key Country Dynamics
      • 8.8.5.3 Regulatory Framework
      • 8.8.5.4 Competitive Scenario
    • 8.8.6 Italy
      • 8.8.6.1 Italy Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.8.6.2 Key Country Dynamics
      • 8.8.6.3 Regulatory Framework
      • 8.8.6.4 Competitive Scenario
    • 8.8.7 Norway
      • 8.8.7.1 Norway Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.8.7.3 Regulatory Framework
      • 8.8.7.4 Competitive Scenario
    • 8.8.8 Denmark
      • 8.8.8.1 Denmark Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.8.8.2 Key Country Dynamics
      • 8.8.8.3 Regulatory Framework
      • 8.8.8.4 Competitive Scenario
    • 8.8.9 Sweden
      • 8.8.9.1 Sweden Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.8.9.2 Key Country Dynamics
      • 8.8.9.3 Regulatory Framework
      • 8.8.9.4 Competitive Scenario
  • 8.9 Asia Pacific
    • 8.9.1 Asia-Pacific Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 8.9.2 Japan
      • 8.9.2.1 Japan Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.9.2.2 Key Country Dynamics
      • 8.9.2.3 Regulatory Framework
      • 8.9.2.4 Competitive Scenario
    • 8.9.3 China
      • 8.9.3.1 China Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.9.3.2 Key Country Dynamics
      • 8.9.3.3 Regulatory Framework
      • 8.9.3.4 Competitive Scenario
    • 8.9.4 India
      • 8.9.4.1 India Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.9.4.2 Key Country Dynamics
      • 8.9.4.3 Regulatory Framework
      • 8.9.4.4 Competitive Scenario
    • 8.9.5 South Korea
      • 8.9.5.1 South Korea Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.9.5.2 Key Country Dynamics
      • 8.9.5.3 Regulatory Framework
      • 8.9.5.4 Competitive Scenario
    • 8.9.6 Thailand
      • 8.9.6.1 Thailand Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.9.6.2 Key Country Dynamics
      • 8.9.6.3 Regulatory Framework
      • 8.9.6.4 Competitive Scenario
    • 8.9.7 Australia
      • 8.9.7.1 Australia Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.9.7.2 Key Country Dynamics
      • 8.9.7.3 Regulatory Framework
      • 8.9.7.4 Competitive Scenario
  • 8.10 Latin America
    • 8.10.1 Latin America Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 8.10.2 Brazil
      • 8.10.2.1 Brazil Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.10.2.2 Key Country Dynamics
      • 8.10.2.3 Regulatory Framework
      • 8.10.2.4 Competitive Scenario
    • 8.10.3 Mexico
      • 8.10.3.1 Mexico Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.10.3.2 Key Country Dynamics
      • 8.10.3.3 Regulatory Framework
      • 8.10.3.4 Competitive Scenario
    • 8.10.4 Argentina
      • 8.10.4.1 Argentina Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.10.4.2 Key Country Dynamics
      • 8.10.4.3 Regulatory Framework
      • 8.10.4.4 Competitive Scenario
  • 8.11 MEA
    • 8.11.1 MEA Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 8.11.2 South Africa
      • 8.11.2.1 South Africa Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.11.2.2 Key Country Dynamics
      • 8.11.2.3 Regulatory Framework
      • 8.11.2.4 Competitive Scenario
    • 8.11.3 Saudi Arabia
      • 8.11.3.1 Saudi Arabia Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.11.3.2 Key Country Dynamics
      • 8.11.3.3 Regulatory Framework
      • 8.11.3.4 Competitive Scenario
    • 8.11.4 UAE
      • 8.11.4.1 UAE Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.11.4.2 Key Country Dynamics
      • 8.11.4.3 Regulatory Framework
      • 8.11.4.4 Competitive Scenario
    • 8.11.5 Kuwait
      • 8.11.5.1 Kuwait Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.11.5.2 Key Country Dynamics
      • 8.11.5.3 Regulatory Framework
      • 8.11.5.4 Competitive Scenario

Chapter 9 Cancer Vaccine Market: Company Profiling

  • 9.1 Company Categorization
  • 9.2 Strategy Mapping
    • 9.2.1 New Product Launch
    • 9.2.2 Partnerships
    • 9.2.3 Acquisition
    • 9.2.4 Collaboration
    • 9.2.5 Funding
  • 9.3 Key Company Market Share Analysis, 2022
  • 9.4 Company Profiles
    • 9.4.1 Merck & Co., Inc.
      • 9.4.1.1 Company Overview
      • 9.4.1.2 Financial Performance
      • 9.4.1.3 Product Benchmarking
      • 9.4.1.4 Strategic Initiatives
    • 9.4.2 GSK plc
      • 9.4.2.1 Company Overview
      • 9.4.2.2 Financial Performance
      • 9.4.2.3 Product Benchmarking
      • 9.4.2.4 Strategic Initiatives
    • 9.4.3 Dendreon Pharmaceuticals LLC.
      • 9.4.3.1 Company Overview
      • 9.4.3.2 Product Benchmarking
      • 9.4.3.3 Strategic Initiatives
    • 9.4.4 Dynavax Technologies.
      • 9.4.4.1 Company Overview
      • 9.4.4.2 Financial Performance
      • 9.4.4.3 Product Benchmarking
      • 9.4.4.4 Strategic Initiatives
    • 9.4.5 Ferring B.V.
      • 9.4.5.1 Company Overview
      • 9.4.5.2 Financial Performance
      • 9.4.5.3 Product Benchmarking
      • 9.4.5.4 Strategic Initiatives
    • 9.4.6 Amgen, Inc.
      • 9.4.6.1 Company Overview
      • 9.4.6.2 Financial Performance
      • 9.4.6.3 Product Benchmarking
      • 9.4.6.4 Strategic Initiatives
    • 9.4.7 Moderna, Inc.
      • 9.4.7.1 Company Overview
      • 9.4.7.2 Financial Performance
      • 9.4.7.3 Product Benchmarking
      • 9.4.7.4 Strategic Initiatives
    • 9.4.8 Sanofi
      • 9.4.8.1 Company Overview
      • 9.4.8.2 Financial Performance
      • 9.4.8.3 Product Benchmarking
      • 9.4.9.4 Strategic Initiatives
    • 9.4.9 AstraZeneca
      • 9.4.9.1 Company Overview
      • 9.4.9.2 Financial Performance
      • 9.4.9.3 Product Benchmarking
      • 9.4.9.4 Strategic Initiatives
    • 9.4.10 Bristol-Myers Squibb Company
      • 9.4.9.1 Company Overview
      • 9.4.9.2 Financial Performance
      • 9.4.9.3 Product Benchmarking
      • 9.4.9.4 Strategic Initiatives